Comparative Safety and Benefit-Risk Profile of Biologics and Oral Treatments for Moderate-to-Severe Plaque Psoriasis: a Network Meta-Analysis of Clinical Trial Data.

In Dermatology
by ClinOwl February 25, 2021

The comparative safety and benefit-risk profiles of moderate-to-severe psoriasis treatments have not been well studied.To compare the short-term (12-16 weeks) and long-term (48-56 weeks) safety and benefit-risk profiles of moderate-to-severe […]

U.S. Burden of Skin and Subcutaneous Diseases Increasing

Can dermatology employers require employees to receive the COVID-19 vaccine?

THE 2020 VISION FOR NEMOLIZUMAB IN ATOPIC DERMATITIS

Expression of retinoid receptors in hand eczema.

S. aureus Agr Virulence Tied to Atopic Dermatitis in Infants

Psoriasis, biological drugs and Coronavirus Disease 2019: Real life experience of two Italian provinces.

Comparative Safety and Benefit-Risk Profile of Biologics and Oral Treatments for Moderate-to-Severe Plaque Psoriasis: a Network Meta-Analysis of Clinical Trial Data.